Ayurveda-focused nutrition and wellness brand Kapiva has raised $60 million in its Series D funding round, a milestone that underscores the growing investor interest in India’s health and wellness sector. The round was co-led by 360 ONE Asset and Vertex Growth, with continued backing from Vertex Ventures Southeast Asia & India and 3one4 Capital.
Deal Structure and Fireside’s Exit
The $60 million transaction was a combination of primary and secondary capital. About $28 million was infused as fresh primary investment, while the rest facilitated secondary sales, enabling early-stage backer Fireside Ventures to exit. The mix not only brings growth capital into the company but also reflects the maturing stage of India’s consumer-focused startups, where early investors begin to realize returns through partial or full exits.
How Kapiva Plans to Use the Funds
Kapiva has proposed a multi-faceted approach to investment the new capital. A good share of the investment will go toward research and development to bolster the scientific validation of its products- a key area for Ayurveda companies wanting a valid basis for being taken seriously at home or abroad. The brand also plans to expand manufacturing capabilities, allowing it to meet rising demand while maintaining quality standards.
In addition, Kapiva will intensify its marketing and brand-building efforts, positioning itself more strongly in the competitive nutraceutical landscape. Another major area of focus is the expansion of its health-tech platform, which will integrate digital tools to support personalised wellness and chronic condition management. By blending Ayurveda with technology, Kapiva hopes to build deeper engagement with consumers looking for long-term health solutions.
Also Read: Is Chakr Innovation Ready to Scale Globally After Securing $23M in Series C?
Products and Distribution Reach
Kapiva, founded in 2015 by Ameve Sharma and Shrey Badhani, was inspired by the goal of making Ayurveda relevant in a format that is appropriate for modern consumers to use today. In the years since, they have built a broad portfolio of products consisting of juices, herbal supplements, vegan protein, teas, oils, and formulas tailored for conditions like diabetes or liver health or hormonal balance.
Kapiva uses an omnichannel strategy, selling directly through its website, through all of the significant e-commerce platforms, and through a rapidly expanding offline channel. The products are currently sold in approximately 40,000 stores across India, exemplifying how it has succeeded in creating an environment where online popularity translates directly into offline distribution. This robust distribution network is expected to be a significant factor in its penetration in growing its domestic market and expanding abroad.
Financial Performance and Growth
Kapiva has shown remarkable progress. It is quickly scaling to a revenue run rate of almost ₹550 crores, an impressive increase over the past few years. Management has indicated that the company is still modestly EBITDA-negative, but is close to breaking even, and expects to be profitable next quarter.
In audited filings for FY24, Kapiva recorded ₹228 crore in revenue, up from roughly half that amount the previous year, representing a doubling of top-line growth. At the same time, its losses narrowed to ₹56 crore, signalling improving efficiency as scale increased. Audited financials for FY25 have not yet been made public, but the company maintains it is on track to sustain its high growth momentum.
Competing in a Crowded Market
Kapiva operates in a highly competitive landscape, going up against both legacy Ayurvedic brands and emerging D2C players. Companies like Wellbeing Nutrition, Gynoveda, and Innovacare are part of this crowded field, where consumer trust, brand differentiation, and scientific credibility often determine winners.
The company’s challenge will consist of growing further without sacrificing margins, being able to support product claims, and working inside the regulatory constructs of Indian and international markets. As Ayurveda gains popularity, quality and innovation will be key to Kapiva’s sustainability as a market leader.
International Expansion and IPO Prospects
In addition to India, Kapiva has expanded to international markets including the United States, Middle East and Europe where the market interest in holistic and Ayurvedic wellness products is on the rise. The U.S. is already producing revenue through a wholly owned subsidiary in that territory to drive its global expansion.
Looking ahead, industry observers believe Kapiva could be gearing up for a public listing. Reports suggest that the Series D round may be one of the company’s last large private raises before it considers an IPO in the next two to three years, depending on market conditions and operational milestones.
Scaling Ayurveda for the Future
Kapiva’s journey illustrates the growing appetite for modern Ayurveda brands that combine tradition with scientific rigor and consumer-friendly formats. With fresh funding, the company is well-positioned to accelerate innovation, expand its offline and international presence, and invest in digital health-tech capabilities.
The coming quarters will be critical: profitability, global execution, and consumer trust will determine whether Kapiva can transform from a fast-growing D2C player into a sustainable global leader in Ayurveda-driven wellness.
Also Read: Gurgaon Flat Turns ₹24 Cr to ₹64 Cr, But XIRR Under 9%
